Colin McCall

Colin advises clients throughout their lifecycle (all the way from start-up/spin-out to multinational listed companies) on the commercialisation of their intellectual property rights. In particular, advising on licensing deals, collaborations and R&D projects, distribution and manufacturing and the IP, commercial and regulatory aspects of M&A, VC investments and IPOs.

Having a 1st class degree in Cell Biology his practice has naturally become focused on the life sciences, healthcare and technology (with a particular focus on med-tech and clean-tech) sectors.

Expertise

Services and Groups

Patents & innovation

Drafting and negotiating patents & know-how commercial agreements

Resolving patents & know-how disputes

Sectors

Life sciences & healthcare

Real estate

Medical devices

CV

Since 2020 Partner, Taylor Wessing

2016 - 2020 Senior Counsel, Taylor Wessing

2010 - 2016 Senior Associate, Taylor Wessing

Career

Since 2020 Partner, Taylor Wessing

2016 - 2020 Senior Counsel, Taylor Wessing

2010 - 2016 Senior Associate, Taylor Wessing

Education

2013 MSc Energy Environmental Technology and Economics, London City University

2005 Diploma in Intellectual Property Law and Practice, Bristol University

2004 Admitted as a lawyer, England, Wales

Additional languages

Awards

Managing Intellectual Property – IP Stars 2024

Featured

Legal 500 UK 2023

Legal 500 UK 2022

Experience

Advising gene therapy company AlveoGene on its complex spinout and launch investment

We have advised AlveoGene, a new UK gene therapy company on its complex spinout from the Gene Therapy Consortium of Imperial College and the Universities of Oxford and Edinburgh focusing on rare respiratory diseases, as well as on its seed round investment.

Press release

Colin McCall

Ross McNaughton

Bella Thornton-Clark

Ceres Power on numerous strategic collaborations

Including on its transformational licensing and equity investment deals done with Weichai Power in China and with Robert Bosch GmbH in respect of Ceres Power's solid oxide fuel cell technology.

Colin McCall

Glenmark Pharma on the sale of its portfolio of CNS products in Poland to Neuraxpharm

Advised Glenmark Pharma on its divestment of its CNS business in Poland including its portfolio of generics and branded generics products and the transfer of its commercial team in Poland to private equity backed Neuraxpharm, a specialty pharmaceutical company focused on the treatment of CNS disorders.

Press release

Colin McCall

Emma Danks

Simon Jupp

Jason Rawkins

Graham Samuel-Gibbon

Oxford BioMedica on its transformational deal with Novartis re: Kymriah

Oxford BioMedica on various commercial and licensing deals including its collaboration, development and licence agreement with Novartis in respect of Kymriah, which became the first gene therapy ever to receive FDA approval and on its manufacturing agreements for clinical and commercial supply of Kymriah to Novartis.

Colin McCall

Apotex's EUR74m sale of subsidiaries to Aurobindo

Apotex on the sale of six European subsidiaries in Belgium, Poland, the Netherlands, Czech Republic and Spain, to Aurobindo for EUR74 million. This highly complex transaction involved the share transfer of subsidiaries in multiple jurisdictions being co-ordinated and managed by our UK team. We simultaneously advised on a multitude of business separation, ongoing product supply agreements and IP licences for the European business to continue operating after being removed from the Apotex group.

Colin McCall

Simon Cohen

Tasmina Goraya, PhD

Jason Rawkins

Simon Jupp

Bart Hunnekens

Roos Seesing

Shire Pharmaceuticals on a global review of its distribution and supply arrangements

Shire Pharmaceuticals on its review and subsequent improvement of its contractual arrangements for distribution and supply of its global portfolio of products in order to make Shire acquisition ready.

Colin McCall